STOCK TITAN

Kneat Announces Record Revenue for Second Quarter 2025

Rhea-AI Impact
(High)
Rhea-AI Sentiment
(Neutral)
Tags

Kneat (OTC: KSIOF) reported strong financial results for Q2 2025, with total revenue reaching $15.4 million, up 32% year-over-year. The company's SaaS revenue grew 31% to $14.1 million, while Annual Recurring Revenue (ARR) increased 43% to $64.8 million.

Q2 2025 highlights include improved gross margin of 75%, EBITDA of $3.8 million, and a reduced net loss of $0.4 million compared to a $3.1 million loss in Q2 2024. The company secured multiple significant client wins, including agreements with a multinational generic pharmaceuticals producer and a global healthcare technology company.

Kneat also announced key executive changes, including the appointment of Dave O'Reilly as CFO and the creation of a Chief Innovation Officer role. The company launched Kneat Gx 9.5, enhancing data management capabilities and validation processes.

Kneat (OTC: KSIOF) ha riportato risultati finanziari solidi nel secondo trimestre 2025, con un fatturato totale che ha raggiunto i 15,4 milioni di dollari, in crescita del 32% rispetto all'anno precedente. I ricavi SaaS dell'azienda sono aumentati del 31%, arrivando a 14,1 milioni di dollari, mentre il Ricavo Annuale Ricorrente (ARR) è cresciuto del 43%, toccando i 64,8 milioni di dollari.

Tra i punti salienti del Q2 2025 si segnalano un miglioramento del margine lordo al 75%, un EBITDA di 3,8 milioni di dollari e una riduzione della perdita netta a 0,4 milioni di dollari, rispetto a una perdita di 3,1 milioni nel Q2 2024. L'azienda ha ottenuto numerosi importanti clienti, tra cui accordi con un produttore multinazionale di farmaci generici e una società globale di tecnologia sanitaria.

Kneat ha inoltre annunciato cambiamenti chiave nel management, con la nomina di Dave O'Reilly come CFO e la creazione del ruolo di Chief Innovation Officer. È stata lanciata la versione Kneat Gx 9.5, che migliora le capacità di gestione dei dati e i processi di validazione.

Kneat (OTC: KSIOF) reportó sólidos resultados financieros en el segundo trimestre de 2025, con ingresos totales que alcanzaron los 15,4 millones de dólares, un aumento del 32% interanual. Los ingresos por SaaS crecieron un 31%, llegando a 14,1 millones de dólares, mientras que los Ingresos Anuales Recurrentes (ARR) aumentaron un 43%, alcanzando los 64,8 millones de dólares.

Entre los aspectos destacados del Q2 2025 se incluyen un margen bruto mejorado del 75%, un EBITDA de 3,8 millones de dólares y una reducción de la pérdida neta a 0,4 millones de dólares en comparación con una pérdida de 3,1 millones en el Q2 2024. La compañía aseguró múltiples contratos importantes, incluyendo acuerdos con un productor multinacional de medicamentos genéricos y una empresa global de tecnología sanitaria.

Kneat también anunció cambios ejecutivos clave, incluyendo el nombramiento de Dave O'Reilly como CFO y la creación del puesto de Chief Innovation Officer. La empresa lanzó Kneat Gx 9.5, mejorando las capacidades de gestión de datos y los procesos de validación.

Kneat (OTC: KSIOF)는 2025년 2분기에 강력한 재무 실적을 보고했으며, 총 매출은 전년 대비 32% 증가한 1,540만 달러에 달했습니다. 회사의 SaaS 매출은 31% 증가하여 1,410만 달러를 기록했으며, 연간 반복 매출(ARR)은 43% 증가하여 6,480만 달러에 이르렀습니다.

2025년 2분기 주요 성과로는 75%의 향상된 총이익률, 380만 달러의 EBITDA, 그리고 2024년 2분기 310만 달러 손실에 비해 감소한 40만 달러의 순손실이 포함됩니다. 회사는 다국적 제네릭 의약품 제조업체 및 글로벌 헬스케어 기술 기업과의 계약을 포함하여 여러 중요한 고객을 확보했습니다.

Kneat는 또한 CFO로 Dave O'Reilly를 임명하고 최고 혁신 책임자(Chief Innovation Officer) 직책을 신설하는 등 주요 임원 변동을 발표했습니다. 또한 데이터 관리 기능과 검증 프로세스를 강화한 Kneat Gx 9.5를 출시했습니다.

Kneat (OTC : KSIOF) a publié de solides résultats financiers pour le deuxième trimestre 2025, avec un chiffre d'affaires total atteignant 15,4 millions de dollars, en hausse de 32 % par rapport à l'année précédente. Les revenus SaaS de la société ont augmenté de 31 % pour atteindre 14,1 millions de dollars, tandis que le revenu annuel récurrent (ARR) a progressé de 43 % à 64,8 millions de dollars.

Les points forts du deuxième trimestre 2025 incluent une marge brute améliorée de 75 %, un EBITDA de 3,8 millions de dollars et une perte nette réduite à 0,4 million de dollars contre une perte de 3,1 millions au deuxième trimestre 2024. L'entreprise a remporté plusieurs contrats importants, notamment avec un producteur multinational de médicaments génériques et une société mondiale de technologie de la santé.

Kneat a également annoncé des changements clés au sein de sa direction, notamment la nomination de Dave O'Reilly au poste de CFO et la création d'un poste de Chief Innovation Officer. La société a lancé Kneat Gx 9.5, améliorant les capacités de gestion des données et les processus de validation.

Kneat (OTC: KSIOF) meldete starke Finanzergebnisse für das zweite Quartal 2025 mit einem Gesamtumsatz von 15,4 Millionen US-Dollar, was einem Anstieg von 32 % gegenüber dem Vorjahr entspricht. Die SaaS-Umsätze des Unternehmens stiegen um 31 % auf 14,1 Millionen US-Dollar, während der Annual Recurring Revenue (ARR) um 43 % auf 64,8 Millionen US-Dollar zunahm.

Zu den Highlights des zweiten Quartals 2025 zählen eine verbesserte Bruttomarge von 75%, ein EBITDA von 3,8 Millionen US-Dollar und ein reduzierter Nettoverlust von 0,4 Millionen US-Dollar im Vergleich zu einem Verlust von 3,1 Millionen im zweiten Quartal 2024. Das Unternehmen sicherte sich mehrere bedeutende Kunden, darunter Verträge mit einem multinationalen Hersteller von Generika und einem globalen Gesundheits-Technologieunternehmen.

Kneat gab außerdem wichtige personelle Veränderungen bekannt, darunter die Ernennung von Dave O'Reilly zum CFO und die Schaffung der Position des Chief Innovation Officer. Zudem wurde Kneat Gx 9.5 eingeführt, das die Datenmanagement-Fähigkeiten und Validierungsprozesse verbessert.

Positive
  • Total revenue increased 32% YoY to $15.4 million in Q2 2025
  • SaaS revenue grew 31% to $14.1 million in Q2 2025
  • Annual Recurring Revenue up 43% YoY to $64.8 million
  • Gross margin improved to 75% from 74% YoY
  • Net loss significantly reduced to $0.4M from $3.1M YoY
  • Multiple new enterprise client wins in pharmaceutical and healthcare sectors
  • First half 2025 showed net income of $1.8M vs $6.4M loss in 2024
Negative
  • Adjusted EBITDA decreased to $0.4M from $1.6M in Q2 2024
  • Company still operating at a net loss of $0.4M in Q2 2025
  • Significant executive turnover with CFO retirement and leadership changes

LIMERICK, Ireland, Aug. 05, 2025 (GLOBE NEWSWIRE) -- kneat.com, inc. (TSX: KSI) (OTC: KSIOF) (“Kneat” or the “Company”) a leader in digitizing and automating validation and quality processes, today announced financial results for the three-month period ended June 30, 2025. All dollar amounts are presented in Canadian dollars unless otherwise stated.

  • Second-quarter 2025 total revenue reaches $15.4 million, an increase of 32% year over year
  • Gross margin for the quarter ended June 30, 2025 reaches 75%
  • Annual Recurring Revenue (ARR)1 at June 30, 2025, grows 43% year over year to $64.8 million.

“We continue on our trajectory towards profitability. New customer wins in the past quarter reached new highs, proving Kneat Gx is the platform of choice. We welcomed new leadership in finance, product and engineering and continued the unrelenting development of our platform.”

- Eddie Ryan, Chief Executive Officer of Kneat. 

Q2 2025 Highlights

  • Total revenues increased 32% to $15.4 million in the second quarter of 2025, compared to $11.7 million for the second quarter of 2024.   
  • SaaS revenue for the second quarter of 2025 grew 31% to $14.1 million, versus $10.8 million for the second quarter of 2024.
  • Second-quarter 2025 gross profit was $11.6 million, up 34% from $8.7 million in gross profit for the second quarter of 2024.
  • Gross margin in the second quarter of 2025 was 75%, compared to 74% for the second quarter of 2024.  
  • EBITDA1 in the second quarter of 2025 was $3.8 million, compared with $0.5 million for the second quarter of 2024.
  • Adjusted EBITDA1 in the second quarter of 2025 was $0.4 million, compared with $1.6 million for the second quarter of 2024.
  • Net loss for the second quarter of 2025 was $0.4 million, compared with a net loss of $3.1 million for the second quarter of 2024.
  • Total ARR1, which includes SaaS license and recurring maintenance fees, was $64.8 million at June 30, 2025, an increase of 43% from $45.4 million at June 30, 2024.

[1] ARR is a supplementary measure. EBITDA and Adjusted EBITDA are non-IFRS measures and are not recognized, defined or standardized measures under IFRS. These measures are defined in the “Supplementary and Non-IFRS Measures” section of this news release.

First Half of 2025 Financial Highlights

  • Total revenues for the six-month period ended June 30, 2025 increased 34% to $30.2 million, compared to $22.4 million for the comparable six-month period in 2024.
  • SaaS revenue grew 36% to $28.0 million for the six months ended June 30, 2025, versus $20.6 million for the comparable period in 2024.
  • Gross profit was $22.6 million, up 36% from $16.6 million in gross profit for the first half of 2024.
  • Gross margin for the first half of 2025 was 75%, compared to 74% for the first half of 2024.
  • EBITDA1 for the first half of 2025 was $9.7 million, compared with $0.0 million for the first half of 2024.
  • Adjusted EBITDA1 for the first half of 2025 was $2.7 million, compared with $2.2 million for the first half of 2024.
  • Net income for the first half of 2025 was $1.8 million, compared with ($6.4) million for the first half of 2024.

Recent Business Highlights

  • In April 2025, Kneat announced that it signed a Services Agreement with a multinational producer of generic pharmaceuticals. The Company, which operates more than a dozen manufacturing facilities around the world and employs more than 20,000 people, will initially use Kneat to digitize its drawing management process.
  • In early May 2025, Kneat saw record attendance at VALIDATE, its annual event convening validation and quality professionals from around the world.  One of the world’s largest events for validation experts to discover, share and apply validation technologies, regulations, and best practices, VALIDATE enabled participants to witness the power of the Kneat Gx platform.
  • In May 2025, Kneat announced that it signed a three-year Master Services Agreement with a leading manufacturer of clinical diagnostics for the healthcare industry. The Company, which operates in more than 40 countries and employs over 14,000 people, will use Kneat Gx initially to digitize its equipment validation process.
  • Also in May 2025, Kneat announced the expansion of its executive leadership team with the addition of a Chief Innovation Officer Role. Co-founder and Chief Product Officer Kevin Fitzgerald transitioned out of his current role and into the Chief Innovation Officer role on June 9th. Donal O’Sullivan, an executive with extensive software development and product management leadership, joined Kneat at that time as Chief Product Officer.
  • In June 2025, Kneat announced that it signed a multi-year Master Services Agreement with a leading global healthcare technology company. The Company, which employs over 50,000 people and manufactures in more than a dozen countries worldwide, will use the Kneat Gx platform initially to digitize its Commissioning, Qualification and Validation workflows for facilities, equipment and computer systems at several lead manufacturing sites.
  • Also in June 2025, Kneat announced the retirement of its CFO Hugh Kavanagh. The role will be filled by Dave O’Reilly, who joined Kneat in July.  Dave served most recently as CFO of Ekco, a leading European managed security service provider, which he helped scale from startup to a business with $200 million in annual revenue. Prior to his time at Ekco he led the international finance function for a $4 billion-SaaS business, Consensus Cloud Solutions/Ziff Davis Inc., formerly J2 Global.  
  • In July, Kneat launched Kneat Gx 9.5, which advances the data management capabilities of our platform. New features include greater management and control over discrete datasets; deeper functionality for defining, regulating and tracing datasets to align with risk-based validation; and more advanced filtering and visibility for Requirements, Risks and Test evidence, critical pillars of effective and efficient validation. These features enable users to save time by leveraging data across more projects than ever before; empowering risk-based validation processes such as Computer Software Assurance; and exerting greater control over traceability that adapts to any workflow.

“Kneat’s long history of solid execution is extended with the results reported today.  I look forward to continuing the disciplined financial stewardship that precedes me in this role, and with it, Kneat’s continuous scaling of the value we deliver to the Life Sciences industry."

- Dave O’Reilly, Chief Financial Officer of Kneat. 

Quarterly Conference Call

Eddie Ryan, Chief Executive Officer of Kneat and Dave O' Reilly, Chief Financial Officer of Kneat, along with outgoing Chief Financial Officer, Hugh Kavanagh, will host a conference call to discuss Kneat’s second-quarter results and hold a Q&A for analysts and investors via webcast on Wednesday, August 6, 2025, at 9:00 a.m. ET.

Interested parties can register for the live webcast via the following link: Register Here.

About Kneat

Kneat Solutions provides leading companies in highly regulated industries with unparalleled efficiency in validation and compliance through its digital validation platform Kneat Gx. As an industry leader in customer satisfaction, Kneat boasts an excellent record for implementation, powered by our user-friendly design, expert support, and on-demand training academy. Kneat Gx is an industry-leading digital validation platform that enables highly regulated companies to manage any validation discipline from end-to-end. Kneat Gx is fully ISO 9001 and ISO 27001 certified, fully validated, and 21 CFR Part 11/Annex 11 compliant. Multiple independent customer studies show up to 40% reduction in documentation cycle times, up to 20% faster speed to market, and a higher compliance standard. For more information visit www.kneat.com.

Supplementary and Non-IFRS Financial Measures

The Company uses supplementary financial measures as key performance indicators in its MD&A and other communications. Management uses both IFRS measures and supplementary, non-IFRS financial measures as key performance indicators when planning, monitoring and evaluating the Company’s performance.

Annual Recurring Revenue (“ARR”)

Kneat management use ARR to evaluate and assess the Company’s performance, identify trends affecting its business, formulate financial projections and make financial decisions. The Company believes that ARR is a useful metric for investors as it provides a measure of the value of the recurring revenue at a point in time (end date of the relevant quarter). ARR is based on signed agreements and indicates the level of recurring revenue that the Company would anticipate reporting in a 12-month period based on the full annual SaaS and maintenance fees for existing customers. In specific circumstances, the Company may utilize pricing incentives for limited contract periods. These incentives are not included in the calculation of ARR. ARR is used by Kneat to assess the expected recurring revenues from the customers that are live on the Kneat Gx platform at the end of the period. ARR is calculated using the licenses delivered to customers at the period end, multiplied by the expected customer retention rate of 100% and multiplied by the full agreed annual SaaS license or maintenance fee. Since many of the customer contracts are in currencies other than the Canadian dollar, the Canadian dollar equivalent is calculated using the related period end exchange rate multiplied by the contracted currency amount.

Earnings before Interest, Taxes, Depreciation and Amortization (“EBITDA”)

EBITDA is calculated as net income (loss) attributable to kneat.com excluding interest income (expense), provision for income taxes, depreciation and amortization. We provide and use this non-IFRS measure of our operating performance to highlight trends in our core business that may not otherwise be apparent when relying solely on IFRS financial measures and to inform financial comparisons with other companies. A reconciliation of EBITDA to IFRS financial measures is provided in the financial statements accompanying this press release.

Adjusted Earnings before Interest, Taxes, Depreciation and Amortization (“Adjusted EBITDA”)

Adjusted EBITDA is calculated as net income (loss) attributable to kneat.com excluding interest income (expense), provision for income taxes, depreciation and amortization, foreign exchange gain and stock-based compensation expense. We provide and use this non-IFRS measure of our operating performance to highlight trends in our core business that may not otherwise be apparent when relying solely on IFRS financial measures and to inform financial comparisons with other companies. A reconciliation of Adjusted EBITDA to IFRS financial measures is provided in the financial statements accompanying this press release.

Cautionary and Forward-Looking Statements

Except for the statements of historical fact contained herein, certain information presented constitutes “forward-looking information” within the meaning of applicable Canadian securities laws. Such forward-looking information includes, but is not limited to, the relationship between Kneat and the customer, Kneat’s business development activities, the use and implementation timelines of Kneat’s software within the customer’s validation processes, the ability and intent of the customer to scale the use of Kneat’s software within the customer’s organization, our ability to win business from new customers and expand business from existing customers, our expected use of the net proceeds from the IPF Facility and the public equity financing completed in both February and October 2024 and the anticipated effects thereof on the business and operations of the company, and the compliance of Kneat’s platform under regulatory audit and inspection. These and other assumptions, risks and uncertainties may cause Kneat’s actual results, performance, achievements and developments to differ materially from the results, performance, achievements or developments expressed or implied by forward-looking statements.

Material risks and uncertainties relating to our business are described under the headings “Cautionary Note Regarding Forward-Looking Statements and Information” and “Risk Factors” in our MD&A dated August 5, 2025, under the heading “Risk Factors” in our Annual Information Form dated February 26, 2025 and in our other public documents filed with Canadian securities regulatory authorities, which are available at www.sedarplus.ca. Forward-looking statements are provided to help readers understand management’s expectations as at the date of this release and may not be suitable for other purposes. Readers are cautioned not to place undue reliance on forward-looking statements. Kneat assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as expressly required by law. Investors should not assume that any lack of update to a previously issued forward-looking statement constitutes a reaffirmation of that statement. Continued reliance on forward-looking statements is at an investor’s own risk.

For further information:

Katie Keita, Kneat Investor Relations
P: + 1-902-450-2660
E: katie.keita@kneat.com



Unaudited Condensed Interim Consolidated Statements of Income/(Loss) and Comprehensive Loss
  Three-month
period ended
June 30, 2025
 Three-month
period ended
June 30, 2024
 Six-month
period ended
June 30, 2025
 Six-month
period ended
June 30, 2024
  $  $  $  $ 
Revenue 15,405,109  11,675,734  30,152,750  22,442,735 
         
Cost of revenue (3,777,809) (2,982,094) (7,600,954) (5,816,109)
         
Gross profit 11,627,300  8,693,640  22,551,796  16,626,626 
         
Expenses        
Research and development (5,702,497) (4,761,889) (10,401,162) (8,807,437)
Sales and marketing (6,129,942) (4,368,485) (11,246,419) (8,400,169)
General and administrative (3,792,405) (2,194,999) (6,304,034) (4,300,588)
         
Operating loss (3,997,544) (2,631,733) (5,399,819) (4,881,568)
         
Finance expense (877,545) (870,905) (1,766,090) (1,738,356)
Interest income 151,053  172,999  349,692  208,075 
Foreign exchange gain 4,429,193  258,049  8,691,793  19,286 
         
(Loss) income before income taxes (294,843) (3,071,590) 1,875,576  (6,392,563)
Income tax expense (84,299) (28,553) (108,729) (44,440)
         
Net (loss) income for the period (379,142) (3,100,143) 1,766,847  (6,437,003)
         
Other comprehensive loss        
Foreign currency translation adjustment to presentation currency (1,833,771) (234,170) (3,832,292) (43,276)
         
Comprehensive loss for the period (2,212,913) (3,334,313) (2,065,445) (6,480,279)
         
(Loss)/Earnings per share - Basic and diluted (0.00) (0.04) 0.02  (0.08)
         
Weighted-average number of common shares outstanding:        
Basic 94,728,598  85,581,420  94,469,559  83,293,224 
Diluted 94,728,598  85,581,420  97,985,267  83,293,224 
         
Reconciliation:        
Net (loss) income for the period (379,142) (3,100,143) 1,766,847  (6,437,003)
Finance expense 877,545  870,905  1,766,090  1,738,356 
Interest income (151,053) (172,999) (349,692) (208,075)
Income tax expense 84,299  28,553  108,729  44,440 
Depreciation charge 181,718  190,394  358,719  381,615 
Amortization of intangible assets charge 3,155,635  2,688,851  6,002,381  4,523,062 
EBITDA 3,769,002  505,561  9,653,074  42,395 
         
Adjustments to EBITDA        
Foreign exchange gain (4,429,193) (258,049) (8,691,793) (19,286)
Stock based compensation 1,090,175  1,338,990  1,787,193  2,151,163 
Adjusted EBITDA 429,984  1,586,502  2,748,474  2,174,272 



kneat.com, inc.
Unaudited Condensed Interim Consolidated Statements of Financial Position
  June 30,
2025
 December 31,
2024
  $ $
Assets    
     
Current assets    
Cash 66,771,997 58,889,572
Amounts receivable 11,176,423 18,377,009
Prepayments 1,861,908 1,870,095
     
  79,810,328 79,136,676
Non-current assets    
Amounts receivable 4,798,361 2,368,006
Property and equipment 8,057,345 6,782,179
Intangible asset 41,999,419 36,290,869
     
Total Assets 134,665,453 124,577,730
     
Liabilities    
     
Current liabilities    
Accounts payable and accrued liabilities 11,071,328 8,580,104
Contract liabilities 26,550,906 21,631,416
Loan payable 6,012,075 4,116,723
Lease liabilities 401,739 434,096
     
  44,036,048 34,762,339
Non-current liabilities    
Contract liabilities 3,063 33,393
Loan payable and accrued interest 17,338,181 19,038,203
Lease liabilities 6,911,364 5,671,952
     
Total Liabilities 68,288,656 59,505,887
     
Equity    
Shareholders’ equity 66,376,797 65,071,843
     
Total Liabilities and Equity 134,665,453 124,577,730



kneat.com, inc.
Unaudited Condensed Interim Consolidated Statement of Cash Flows
  Six-month
period ended
June 30, 2025
 Six-month
period ended
June 30, 2024
Operating activities $ $
Net income (loss) for the period 1,766,847  (6,437,003)
Charges to income (loss) not involving cash:    
Depreciation of property and equipment 358,719  381,615 
Share-based compensation 1,787,193  2,151,163 
Interest expense 1,672,870  1,738,356 
Tax expense 108,729  44,440 
Amortization of the intangible asset 6,002,381  4,523,062 
Amortization of loan issuance costs 93,220  76,194 
Foreign exchange gain (8,691,793) (19,286)
(Decrease)/increase in non-current contract liabilities (31,359) 38,241 
Net change in non-cash operating working capital related to operations 12,481,190  7,533,596 
Net cash provided by operating activities 15,547,997  10,030,378 
     
Financing activities    
Proceeds received from public equity financing -  20,000,110 
Share issuance costs associated with public equity financing -  (1,626,257)
Payment of principal and interest on loans payable (3,154,648) (1,232,889)
Proceeds from the exercise of stock options 989,061  1,051,787 
Repayment of lease liabilities (394,650) (364,423)
Net cash (used in)/provided by financing activities (2,560,237) 17,828,328 
     
Investing activities    
Additions to the intangible asset (10,599,886) (9,675,371)
Additions to property and equipment (96,462) (50,397)
Collection of research and development tax credits 1,887,789  2,336,619 
Net cash used in investing activities (8,808,559) (7,389,149)
     
Effects of exchange rates on cash 3,703,224  170,762 
     
Net change in cash during the period 7,882,425  20,640,319 
     
Cash – Beginning of period 58,889,572  15,252,526 
     
Cash – End of period 66,771,997  35,892,845 

FAQ

What was Kneat's (KSIOF) revenue growth in Q2 2025?

Kneat reported Q2 2025 revenue of $15.4 million, representing a 32% increase compared to $11.7 million in Q2 2024.

How much did Kneat's SaaS revenue grow in Q2 2025?

Kneat's SaaS revenue grew 31% to reach $14.1 million in Q2 2025, compared to $10.8 million in Q2 2024.

What is Kneat's current Annual Recurring Revenue (ARR)?

Kneat's ARR reached $64.8 million as of June 30, 2025, showing a 43% increase from $45.4 million in the previous year.

How did Kneat's profitability change in Q2 2025?

Kneat reduced its net loss to $0.4 million in Q2 2025, compared to a $3.1 million loss in Q2 2024, while maintaining a strong gross margin of 75%.

What major business developments did Kneat announce in Q2 2025?

Kneat announced several key developments including new client wins in pharmaceutical and healthcare sectors, the appointment of a new CFO Dave O'Reilly, creation of a Chief Innovation Officer role, and the launch of Kneat Gx 9.5 platform upgrade.
Kneat Com

OTC:KSIOF

KSIOF Rankings

KSIOF Latest News

KSIOF Stock Data

370.57M
55.95M
21.39%
15.6%
Health Information Services
Healthcare
Link
Ireland
Limerick